TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7898227
Drug: LDL apheresis
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL apheresis plus simvastatin 40 mg daily
Study: 7898227
Drug: Colestipol 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestipol 20 g plus simvastatin 40 mg daily
Study: 2803775
Drug: Topical fusidic
Normalized name: fusidate Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical fusidic acid 1%
Study: 2803775
Drug: Topical chloramphenicol
Normalized name: chloramphenicol Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical chloramphenicol 0.5%
Study: 1100301
Drug: Penfluridol (30,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penfluridol (30, 60, and 120 mg weekly)
Study: 28255102
Drug: Triple-Antiplatelet Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-Antiplatelet Therapy (TAPT) with cilostazol
Study: 28255102
Drug: Dual-Antiplatelet Therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-Antiplatelet Therapy (DAPT) (aspirin and clopidogrel)
Study: 23414490
Drug: IL-6 -174
Normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-6 -174 CC genotype
Study: 17071020
Drug: Bi-weekly judicial
Normalized name: selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bi-weekly judicial status hearings
Study: 26051110
Drug: Weekly 35
Normalized name: norelgestromin
DrugBank: Norelgestromin (DB06713)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly 35 mg risedronate
Study: 26051110
Drug: Daily 5
Normalized name: Walgreens Gold Seal One Daily 50 Plus Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily 5 mg risedronate
Study: 23677653
Drug: Daily injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily injections of filgrastim (100 μg/m(2))
Study: 23677653
Drug: DA‐3031 3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA‐3031 3.6 mg
Study: 23677653
Drug: DA‐3031 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA‐3031 6 mg
Study: 21596879
Drug: Fospropofol IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fospropofol IV infusion with a bolus and increased infusion rate for agitation events (infusion/bolus)
Study: 21596879
Drug: Fospropofol IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fospropofol IV infusion with an increased infusion rate for agitation events (infusion only)
Study: 21596879
Drug: Propofol IV
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol IV infusion with an increased infusion rate for agitation events
Study: 12780882
Drug: Open treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open treatment alone (Open Group)
Study: 8883120
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral alendronate
Study: 1595914
Drug: Intraarticular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular morphine (0.03%, with or without 1:200,000 epinephrine)
Study: 27209505
Drug: Cisplatin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (100 mg/m2) or Cisplatin (75 mg/m2) plus Tirapazamine with concurrent radiation therapy (70 Gy over 7 weeks)
Study: 24638013
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg for 1 year
Study: 7912725
Drug: Taxotere (docetaxel)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Taxotere (docetaxel) at 110 mg/m2 per course
Study: 2319479
Drug: Caffeine 100
Normalized name: caffeine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 100 mg
Study: 31222342
Drug: Methionine requirements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionine requirements expressed as g/MJ ME of diet
Study: 22692114
Drug: 600 ml
Normalized name: urinary bag 600 mL-10" MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 ml of water (W)
Study: 22692114
Drug: Carbohydrate-electrolyte solution
Normalized name: CARBOHYDRATE/ELECTROLYTES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-electrolyte solution with 3% or light carbohydrate (CES-L, 20 mM Na)
Study: 22692114
Drug: Carbohydrate-electrolyte solution
Normalized name: CARBOHYDRATE/ELECTROLYTES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-electrolyte solution with 6% carbohydrate (CES, 20 mM Na)
Study: 20071896
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy and rhythmic exercise (twice a week for 8 weeks)
Study: 9022524
Drug: Aspartame treatment
Normalized name: Aspartame
DrugBank: Aspartame (DB00168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame treatment group
Study: 9022524
Drug: No aspartame
Normalized name: Aspartame
DrugBank: Aspartame (DB00168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No aspartame treatment group
Study: 3510822
Drug: Oxitropium bromide
Normalized name: oxitropium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxitropium bromide (200 micrograms) and fenoterol (400 micrograms) combination
Study: 30710391
Drug: CEP-26401 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEP-26401 (5 μg)
Study: 30710391
Drug: CEP-26401 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEP-26401 (25 μg)
Study: 30710391
Drug: CEP-26401 (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEP-26401 (125 μg)
Study: 26865535
Drug: Glipizide (≤20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glipizide (≤20 mg daily)
Study: 17931408
Drug: Cocaine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (0.2 mg/kg) administered under 100% probability ('unblinded')
Study: 17931408
Drug: Cocaine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (0.2 mg/kg) administered under 33% probability ('blinded')
Study: 10839761
Drug: Azithromycin treatment
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin treatment for 3 months
Study: 9286227
Drug: Ethanol-containing solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol-containing solution (4% w/v, 4.06 kcal/min, 1190 mosmol/kg)
Study: 9286227
Drug: Ethanol-free solution
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol-free solution (2.64 kcal/min, 160 mosmol/kg)
Study: 9286227
Drug: Ethanol-free hyperosmolar
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol-free hyperosmolar solution (4.06 kcal/min, 1160 mosmol/kg)
Study: 24800966
Drug: Web-based guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based guided self-help course (Happy@Work), 6 weekly lessons
Study: 22418581
Drug: Antibiotic-impregnated EVD
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic-impregnated EVD catheters
Study: 15590212
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol therapy (50 microg per day) for 3 months
Study: 10100650
Drug: Single treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single treatment IPL
Study: 10100650
Drug: Double treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double treatment IPL
Study: 8728345
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of mycophenolate mofetil (1.5 g)
Study: 8728345
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of mycophenolate mofetil (1.5 g)
Study: 8728345
Drug: Both routes
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both routes (oral and intravenous)
Study: 6344625
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg acetaminophen
Study: 29020251
Drug: Celecoxib (100-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (100-200 mg bid)
Study: 29020251
Drug: Ibuprofen (600-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (600-800 mg tid)
Study: 29020251
Drug: Naproxen (375-500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (375-500 mg bid)
Study: 19950736
Drug: Microcurrent skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microcurrent skin patches (two adhesive electrodes)
Study: 19950736
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion with fentanyl (Control Group)
Study: 17518957
Drug: Profylin fluoride
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Profylin fluoride gel with buffering components
Study: 17518957
Drug: Profylin fluoride
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Profylin fluoride gel without buffering components
Study: 27618821
Drug: Genexol-PM 260
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genexol-PM 260 mg/m2
Study: 27618821
Drug: Genexol 175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genexol 175 mg/m2
Study: 23890047
Drug: Evening administration
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening administration of low-dose aspirin
Study: 21773673
Drug: Travoprost 0.004%/timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Travoprost 0.004%/timolol 0.5% fixed combination (TTFC)
Study: 19384192
Drug: Valsartan/HCTZ (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan/HCTZ (160 mg/25 mg, titrated to 320/25 mg)
Study: 19384192
Drug: Amlodipine/HCTZ (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/HCTZ (5 mg/25 mg, titrated to 10/25 mg)
Study: 17107398
Drug: Lactobacillus rhamnosus
Normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus rhamnosus (LGG) 10 x 10^9 colony-forming units daily for 8 weeks
Study: 15902479
Drug: 2-hourly clamping
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2-hourly clamping of drain and release for 10 min
Study: 10687944
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg PPA
Study: 10687944
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg PPA
Study: 10687944
Drug: PPA (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPA (both doses)
Study: 6130599
Drug: Antacid tablets
Normalized name: Calcium Carbonate 500 MG Oral Tablet, Chewable [GOOD SENSE ANTACID TABLETS]
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antacid tablets (total acid‐neutralizing capacity, 280 mmol/day)
Study: 6130599
Drug: Antacid tablets
Normalized name: Calcium Carbonate 500 MG Oral Tablet, Chewable [GOOD SENSE ANTACID TABLETS]
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antacid tablets
Study: 26926659
Drug: Problem solving
Normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem solving therapy (PST)
Study: 30343455
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three therapies
Study: 24411921
Drug: Tipifarnib 300
Normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tipifarnib 300 mg orally twice daily on days 1‐21
Study: 24411921
Drug: Tipifarnib 600
Normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tipifarnib 600 mg orally twice daily on days 1‐21
Study: 24411921
Drug: Tipifarnib 300
Normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tipifarnib 300 mg orally twice daily on days 1‐7 and 15‐21
Study: 24411921
Drug: Tipifarnib 600
Normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tipifarnib 600 mg orally twice daily on days 1‐7 and 15‐21
Study: 23160054
Drug: School Well-Being
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: School Well-Being Therapy intervention
Study: 15713438
Drug: Chlorinated solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorinated solution of neutral red with ultraviolet-A light exposure
Study: 12589898
Drug: Psychological treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological treatments for prodromal symptoms
Study: 11149790
Drug: Dexamethasone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (10 mg) preoperatively
Study: 11149790
Drug: Dexamethasone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (10 mg) postoperatively
Study: 11149790
Drug: Dexamethasone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (10 mg) preoperatively or postoperatively
Study: 27757820
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (occupational therapy)
Study: 25308787
Drug: Biweekly induction
Normalized name: Biweekly Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biweekly induction with intravitreal bevacizumab (every 2 weeks for 3 consecutive injections)
Study: 25308787
Drug: Monthly induction
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly induction with intravitreal bevacizumab (every 4 weeks for 3 consecutive injections)
Study: 25308787
Drug: Immediate pro
Normalized name: Climara Pro
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate pro re nata (prn) after the first injection
Study: 24180715
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anaesthesia (TIVA) using propofol plus remifentanil
Study: 19023899
Drug: Scheduled maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheduled maintenance therapy (group A) - IFX every 2 months
Study: 19023899
Drug: On demand
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: On demand maintenance therapy (group B) - IFX on relapse
Study: 15037323
Drug: Gatifloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gatifloxacin (400 mg)
Study: 9929929
Drug: Diet with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet with increased omega-3 PUFA in addition to ibuprofen treatment
Study: 9929929
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no omega-3 PUFA diet, only ibuprofen)
Study: 8306366
Drug: IL‐2 i.a.
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL‐2 i.a. infusion for 4 days (Group A, n = 3)
Study: 8306366
Drug: IFN alpha
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN alpha s.c. for 5 days followed by continuous IL‐2 i.v. infusion for 5 days (Group B, n = 4)
Study: 8306366
Drug: IL‐2 i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL‐2 i.v. infusion for 4 days with s.c. IFN alpha on days 1 and 4 (Group C, n = 4)
Study: 3378553
Drug: Atropine sulphate
Normalized name: Atropine sulphate
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine sulphate (same dose as Group 2)
Study: 3378553
Drug: Glycopyrrolate (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate (same dose as Group 2)
Study: 23826104
Drug: 800 IU
Normalized name: Vitamin E 800 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 IU ergocalciferol daily until delivery
Study: 23826104
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral bolus of 200,000 IU cholecalciferol
Study: 24025658
Drug: Medicare Part
Normalized name: benzocaine / menthol Medicated Pad [Medicaine Sting]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicare Part D prescription drug plan (PDP) with covered drugs
Study: 24025658
Drug: Medicare Part
Normalized name: benzocaine / menthol Medicated Pad [Medicaine Sting]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicare Part D prescription drug plan (PDP) with noncovered drugs
Study: 24025658
Drug: Prior authorization
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior authorization or step therapy for covered drugs
Study: 24025658
Drug: Medicare Part
Normalized name: benzocaine / menthol Medicated Pad [Medicaine Sting]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicare Part D prescription drug plan (PDP)
Study: 20422423
Drug: 600 μg
Normalized name: P.G. 600 KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 μg misoprostol orally
Study: 20422423
Drug: 600 μg
Normalized name: P.G. 600 KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 μg misoprostol rectally
Study: 16779765
Drug: Playing mahjong
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Playing mahjong twice a week (n = 33)
Study: 12707981
Drug: Creatine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine (3 g daily for 3 months)
Study: 10946888
Drug: Continuous GH
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous GH treatment at 33 microg/kg x day
Study: 10946888
Drug: Continuous GH
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous GH treatment at 67 microg/kg x day
Study: 10946888
Drug: Discontinuous GH
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuous GH treatment (average dose 32 microg/kg x day over 6 yr)
Study: 1451716
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg b.d.
Study: 6207197
Drug: Antithyroid drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithyroid drug and T4 (group I)
Study: 6207197
Drug: β1‐selective adrenoreceptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: β1‐selective adrenoreceptor blocking agent metoprolol (group II)
Study: 22196428
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy modalities (PT: ultrasound therapy and hot pack)
Study: 17909308
Drug: Selegiline ODT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline ODT (1.25 mg/d for 6 weeks, then 2.5 mg/d for 6 weeks)
Study: 14979606
Drug: Vascor (test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vascor (test formulation of simvastatin 10 mg)
Study: 14979606
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available preparation (reference formulation of simvastatin 10 mg)
Study: 9695205
Drug: Povidone-iodine solution
Normalized name: POVIDONE-IODINE 1 g in 100 mL TOPICAL LIQUID [Loris Povidone-Iodine Solution]
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone-iodine solution rinsing 4 times daily
Study: 8590895
Drug: Liposomal melanoma
Normalized name: melanoma vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal melanoma vaccine combined with low-dose regional IL-2 (arm C)
Study: 8590895
Drug: Low-dose regional
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose regional IL-2 only (arm D)
Study: 8590895
Drug: Liposomal melanoma
Normalized name: melanoma vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal melanoma vaccine alone (arm A)
Study: 8590895
Drug: Liposomal melanoma
Normalized name: melanoma vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal melanoma vaccine combined with systemic IL-2 (arm B)
Study: 2666454
Drug: Diltiazem (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (120 mg bid to 180 mg bid)
Study: 404027
Drug: Limited field
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Limited field irradiation followed by MOPP chemotherapy
Study: 26806185
Drug: Glucosamine sulfate
Normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucosamine sulfate (1500mg once daily)
Study: 25561135
Drug: Phlebodium decumanum
Normalized name: Phlebodium aureum leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phlebodium decumanum (4 capsules of 400 mg/capsule, daily)
Study: 25561135
Drug: Phlebodium decumanum
Normalized name: Phlebodium aureum leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phlebodium decumanum (4 capsules of 400 mg/capsule, daily) plus coenzyme Q10 (4 capsules of 30 mg/capsule, daily)
Study: 21844282
Drug: Intensive rehabilitation
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive rehabilitation treatment (IRT) - 4 weeks of inpatient physical therapy including treadmill and stabilometric platform training.
Study: 21844282
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received only pharmacological treatment and was invited to practice generic physical exercise at home.
Study: 17467956
Drug: Dihydrexidine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydrexidine (20 mg subcutaneously)
Study: 15684319
Drug: Protein supplements
Normalized name: PROTEIN SUPPLEMENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein supplements
Study: 12148107
Drug: Daily short
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily short hemodialysis (DHD; six 2-hour sessions per week)
Study: 8773035
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg Ginkgo biloba extract at 6 hourly intervals along with routine management
Study: 8773035
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets of same size, shape and colour, given in the same way as Ginkgo biloba
Study: 2405893
Drug: Transdermal hyoscine
Normalized name: HYOSCINE HYDROBROMIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal hyoscine (Scopoderm, Ciba‐Geigy)
Study: 6161281
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment modality (vitrectomy plus photocoagulation)
Study: 21975269
Drug: Hormonal contraception
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormonal contraception (injectable and oral)